Consequently, inhibitors of the integrated stress response, such as ISRIB, and other small molecules that target the endoplasmic reticulum stress response, hold promise as potential therapeutic strategies for addressing C9orf72 ALS/FTD. Here, C9orf72 is linked to amyotrophic lateral sclerosis.